How XERMELO can help
How XERMELO was studied
In the TELESTAR study, the clinical study that led to the FDA approval of XERMELO, XERMELO + somatostatin analog (SSA) was compared with SSA injections alone in 90 people (45 per test group) with carcinoid syndrome diarrhea (CSD). Participants were having between 4 to 12 bowel movements (BMs) per day and were already on a steady SSA dose for at least 3 months. All participants were followed for 12 weeks and recorded diarrhea frequency in a daily diary.
XERMELO pills + SSA injections provide long-term relief for CSD
TELESTAR showed meaningful reductions in CSD symptoms. XERMELO was studied in multiple long-term safety studies. The average treatment was 92 weeks.

XERMELO + SSA reduced average daily BM frequency 2X more than SSA injections alone (-1.4 vs -0.6, respectively).
Give XERMELO 12 weeks to work
In the TELESTAR study, almost 9 out of 10 people with CSD (89%) taking XERMELO pills plus SSA injections had a reduction in diarrhea frequency at 12 weeks. In the same study, only 69% of patients on SSA injections alone reduced their BM frequency.

XERMELO reduced serotonin levels
CSD occurs when there is too much serotonin in the gut. When serotonin breaks down in your body, it becomes 5-hydroxyindoleacetic acid (5-HIAA). People with CSD often have high levels of 5-HIAA. In the TELESTAR study, about 57% of patients that were enrolled had elevated 5-HIAA levels at baseline, while 27% had normal levels and ~15% had unknown levels at baseline.
At the end of the TELESTAR study, patients' 5-HIAA levels were measured. In the group treated with XERMELO + SSA injections, 5-HIAA levels were reduced by 40.1 mg. In patients treated with SSA alone, 5‑HIAA levels showed an increase of 11.5 mg.
Your doctor may measure your 5-HIAA to see how much serotonin is in your body.
Actor portrayals.How to talk to your doctor about XERMELO
Complete a few questions and download your answers to create a helpful discussion guide for your next appointment.
Create discussion guide